INKTMiNK Therapeutics, Inc.

Nasdaq minktherapeutics.com


$ 0.97 $ -0.01 (-1.13 %)    

Monday, 06-May-2024 14:38:05 EDT
QQQ $ 440.32 $ 0.07 (0.02 %)
DIA $ 388.70 $ 0.29 (0.07 %)
SPY $ 517.26 $ 0.57 (0.11 %)
TLT $ 90.79 $ 0.55 (0.61 %)
GLD $ 214.23 $ -0.99 (-0.46 %)
$ 0.9301
$ 0.97
$ 0.00 x 0
$ 0.00 x 0
$ 0.97 - $ 0.97
$ 0.75 - $ 3.34
58,227
na
31.96M
$ 1.51
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-21-2024 12-31-2023 10-K
2 11-14-2023 09-30-2023 10-Q
3 08-10-2023 06-30-2023 10-Q
4 05-11-2023 03-31-2023 10-Q
5 03-24-2023 12-31-2022 10-K
6 11-03-2022 09-30-2022 10-Q
7 08-15-2022 06-30-2022 10-Q
8 05-13-2022 03-31-2022 10-Q
9 03-18-2022 12-31-2021 10-K
10 11-29-2021 09-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 mink-therapeutics-announces-preclinical-activity-of-mink-215-against-colorectal-cancer-liver-metastases-at-aacr

MiNK-215 eliminated MSS colorectal cancer liver metastases in human organoid models MiNK-215 exhibits potent anti-tumor activit...

 why-byrna-technologies-shares-are-trading-higher-by-around-7-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of Byrna Technologies Inc. (NASDAQ: BYRN) rose sharply during Friday’s session after the company reported better-than-ex...

 hc-wainwright--co-maintains-buy-on-mink-therapeutics-lowers-price-target-to-9

HC Wainwright & Co. analyst Emily Bodnar maintains MiNK Therapeutics (NASDAQ:INKT) with a Buy and lowers the price targe...

 mink-therapeutics-q4-eps-016-misses-015-estimate

MiNK Therapeutics (NASDAQ:INKT) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $...

 earnings-scheduled-for-march-21-2024

Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per s...

 mink-announces-preclinical-data-showcasing-activity-of-mink-215-against-colorectal-cancer-liver-metastases-at-aacr-2024

MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and co...

 mink-therapeutics-inc-announces-first-refractory-gastric-cancer-patient-dosed-in-phase-2-trial-with-novel-combination-of-cos-allogeneic-inkt-cell-therapy-and-agenus-botensilimab-and-balstilimab

Dr. Yelena Janjigian, Chief of GI Cancers, Leads Investigator Sponsored Study at Memorial Sloan Kettering Cancer Center Trial i...

 mink-therapeutics-agent-797-presents-results-in-the-treatment-of-severe-acute-respiratory-distress-published-in-nature-communications

MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and co...

 mink-therapeutics-minks-agent-797-offers-new-hope-in-overcoming-ici-resistance-in-pd-1-refractory-gastric-cancer---published-in-oncogene

MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and co...

 mink-therapeutics-q3-2023-eps-015-beats-018-estimate

MiNK Therapeutics (NASDAQ:INKT) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0...

 earnings-scheduled-for-november-9-2023

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on re...

 mink-therapeutics-presents-clinical-activity-and-long-term-persistence-of-allogeneic-inkt-cells-in-solid-tumors-at-sitc-2023

Clinical responses and durable activity with agenT-797 monotherapy and in combination with anti-PD-1First-of-a-kind persistence...

 sacks-parente-golf-and-3-other-stocks-under-2-insiders-are-buying

The Dow Jones closed higher by more than 300 points on Monday. When insiders purchase or sell shares, it indicates their confid...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION